AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

The mammalian target of rapamycin (mTOR) kinase forms two multiprotein complexes, mTORC1 and mTORC2, which regulate cell growth, cell survival, and autophagy. Allosteric inhibitors of mTORC1, such as rapamycin, have been extensively used to study tumor cell growth, proliferation, and autophagy but have shown only limited clinical utility. Here, we describe AZD8055, a novel ATP-competitive inhibitor of mTOR kinase activity, with an IC50 of 0.8 nmol/L.

Read the full abstract on PubMed →

Chresta, C. M., et al. (2009). AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer research. https://doi.org/10.1158/0008-5472.CAN-09-1751

@article{CHR2009,
  author       = {Chresta, C. M. and Pass, M. and others},
  title        = {{AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity}},
  journal      = {Cancer research},
  year         = {2009},
  doi          = {10.1158/0008-5472.CAN-09-1751},
  note         = {PMID: 20028854},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record CHR2009) [Data set]. https://mtor-atlas.org/study/CHR2009/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_CHR2009,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record CHR2009},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/CHR2009/},
  doi          = {10.5281/zenodo.22059963}
}